Page David, Costa Vítor Santos, Natarajan Sriraam, Barnard Aubrey, Peissig Peggy, Caldwell Michael
University of Wisconsin-Madison.
CRACS-INESC TEC and FCUP.
Proc AAAI Conf Artif Intell. 2012 Jul;2012:790-793.
The pharmaceutical industry, consumer protection groups, users of medications and government oversight agencies are all strongly interested in identifying adverse reactions to drugs. While a clinical trial of a drug may use only a thousand patients, once a drug is released on the market it may be taken by millions of patients. As a result, in many cases adverse drug events (ADEs) are observed in the broader population that were not identified during clinical trials. Therefore, there is a need for continued, post-marketing surveillance of drugs to identify previously-unanticipated ADEs. This paper casts this problem as a , related to and provides an initial evaluation of this approach based on experiments with an actual EMR/EHR and known adverse drug events.
制药行业、消费者保护组织、药物使用者和政府监管机构都对识别药物不良反应有着浓厚兴趣。虽然一种药物的临床试验可能仅涉及一千名患者,但一旦药物投放市场,可能会有数百万人使用。因此,在许多情况下,在更广泛的人群中会观察到临床试验期间未识别出的药物不良事件(ADE)。所以,需要对药物进行持续的上市后监测,以识别先前未预料到的ADE。本文将这个问题视为一个与……相关的问题,并基于对实际电子病历/电子健康记录以及已知药物不良事件的实验,对这种方法进行了初步评估。